BR112019011462A2 - peptídeo coagonista de gip/glp-1, e, peptídeo para uso no tratamento e/ou profilaxia da doença de alzheimer clínica. - Google Patents

peptídeo coagonista de gip/glp-1, e, peptídeo para uso no tratamento e/ou profilaxia da doença de alzheimer clínica.

Info

Publication number
BR112019011462A2
BR112019011462A2 BR112019011462A BR112019011462A BR112019011462A2 BR 112019011462 A2 BR112019011462 A2 BR 112019011462A2 BR 112019011462 A BR112019011462 A BR 112019011462A BR 112019011462 A BR112019011462 A BR 112019011462A BR 112019011462 A2 BR112019011462 A2 BR 112019011462A2
Authority
BR
Brazil
Prior art keywords
peptide
gip
glp
disease
treatment
Prior art date
Application number
BR112019011462A
Other languages
English (en)
Inventor
Hölscher Christian
Original Assignee
Lancaster Univ Business Enterprises Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lancaster Univ Business Enterprises Limited filed Critical Lancaster Univ Business Enterprises Limited
Publication of BR112019011462A2 publication Critical patent/BR112019011462A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

aspectos e modalidades da presente invenção referem-se ao tratamento de distúrbios neurológicos, tais como, por exemplo, doença de alzheimer e doença de parkinson. particularmente, certas modalidades referem-se a peptídeos coagonistas de gip/glp-1 para utilização no tratamento destes dois distúrbios neurológicos. também estão incluídas na presente invenção, entre outros, composições farmacêuticas compreendendo os peptídeos coagonistas de gip/glp-1, juntamente com métodos de tratamento de tais distúrbios, bem como outras matérias.
BR112019011462A 2016-12-05 2017-12-04 peptídeo coagonista de gip/glp-1, e, peptídeo para uso no tratamento e/ou profilaxia da doença de alzheimer clínica. BR112019011462A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1620611.2A GB201620611D0 (en) 2016-12-05 2016-12-05 Treatment of neurological diseases
PCT/GB2017/053655 WO2018104718A1 (en) 2016-12-05 2017-12-04 Treatment of neurological diseases

Publications (1)

Publication Number Publication Date
BR112019011462A2 true BR112019011462A2 (pt) 2019-10-22

Family

ID=58159786

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019011462A BR112019011462A2 (pt) 2016-12-05 2017-12-04 peptídeo coagonista de gip/glp-1, e, peptídeo para uso no tratamento e/ou profilaxia da doença de alzheimer clínica.

Country Status (24)

Country Link
US (2) US11220534B2 (pt)
EP (1) EP3548061B1 (pt)
JP (1) JP7099729B2 (pt)
KR (1) KR102600128B1 (pt)
CN (1) CN110312520B (pt)
AU (1) AU2017371811B2 (pt)
BR (1) BR112019011462A2 (pt)
CA (1) CA3044797A1 (pt)
CL (1) CL2019001512A1 (pt)
CO (1) CO2019006979A2 (pt)
CY (1) CY1123623T1 (pt)
DK (1) DK3548061T3 (pt)
ES (1) ES2833408T3 (pt)
GB (1) GB201620611D0 (pt)
HR (1) HRP20201959T1 (pt)
HU (1) HUE052766T2 (pt)
LT (1) LT3548061T (pt)
MX (1) MX2019006495A (pt)
PT (1) PT3548061T (pt)
RS (1) RS61230B1 (pt)
RU (1) RU2755997C2 (pt)
SI (1) SI3548061T1 (pt)
WO (1) WO2018104718A1 (pt)
ZA (1) ZA201903003B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201620611D0 (en) * 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
EP4185607A1 (en) 2020-07-22 2023-05-31 Novo Nordisk A/S Co-agonists at glp-1 and gip receptors suitable for oral delivery
CN114617956B (zh) * 2020-12-10 2023-10-03 江苏中新医药有限公司 一种高效降糖的蛋白质药物
CN114042149B (zh) * 2021-12-03 2023-06-16 中国人民解放军空军军医大学 D-Ala2-GIP用于制备治疗焦虑症药物的应用
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
WO2023151594A1 (en) * 2022-02-11 2023-08-17 Hangzhou Sciwind Biosciences Co., Ltd. A composition comprising gip receptor agonists and glp-1 receptor agonists and use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008132149A (ru) 2006-01-05 2010-02-10 Юниверсити Оф Юта Рисерч Фаундейшн (Us) Способы и композиции, имеющие отношение к улучшенным свойствам фармакологических средств, целенаправленно действующих на нервную систему
PL2300035T3 (pl) * 2008-06-17 2016-04-29 Univ Indiana Res & Tech Corp Mieszani agoniści na bazie GIP do leczenia zaburzeń metabolicznych i otyłości
JP2012505637A (ja) 2008-10-15 2012-03-08 アンジオケム，インコーポレーテッド Ｇｌｐ−１アゴニストのコンジュゲート及びその使用
RU2012136450A (ru) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
EP2621945B1 (en) 2010-09-28 2018-04-11 NoNO Inc. Nd2 peptides and methods of treating neurological disease
TWI559929B (en) * 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
EP2766094B1 (en) 2011-10-10 2019-03-06 Lancaster University Business Enterprises Limited Compositions for binding to amyloid proteins
IN2014MN02304A (pt) 2012-05-03 2015-08-07 Zealand Pharma As
RU2015101697A (ru) * 2012-06-21 2016-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, обладающие активностью рецептора gip
SG10202001285XA (en) 2014-05-28 2020-04-29 Nono Inc Chloride salt of tat-nr2b9c
GB2528436A (en) 2014-07-15 2016-01-27 Lancaster Univ Business Entpr Ltd Treatment of neurological diseases
US20160143920A1 (en) * 2014-10-22 2016-05-26 Morris Notelovitz Composition, formulations and methods of making and using botanicals and natural compounds for the promotion of healthy brain aging
US20170112897A1 (en) 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance
WO2017075522A2 (en) 2015-10-28 2017-05-04 Tufts University Glp-2 polypeptides with improved proteolytic stability, and methods of preparing and using same
WO2017210168A1 (en) 2016-06-02 2017-12-07 Indiana University Research And Technology Corporation Aqueously soluble and chemically stable depsi glucagon agonists
GB201620611D0 (en) * 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases

Also Published As

Publication number Publication date
CN110312520B (zh) 2023-01-24
DK3548061T3 (da) 2020-12-14
JP7099729B2 (ja) 2022-07-12
AU2017371811B2 (en) 2022-03-10
ES2833408T3 (es) 2021-06-15
PT3548061T (pt) 2020-11-24
RU2019118165A3 (pt) 2021-03-05
US20200079832A1 (en) 2020-03-12
EP3548061B1 (en) 2020-09-09
KR102600128B1 (ko) 2023-11-08
HRP20201959T1 (hr) 2021-04-16
SI3548061T1 (sl) 2021-04-30
KR20190101367A (ko) 2019-08-30
RU2019118165A (ru) 2021-01-11
RU2755997C2 (ru) 2021-09-24
US11851468B2 (en) 2023-12-26
EP3548061A1 (en) 2019-10-09
AU2017371811A1 (en) 2019-06-13
RS61230B1 (sr) 2021-01-29
MX2019006495A (es) 2019-11-05
CY1123623T1 (el) 2022-03-24
US11220534B2 (en) 2022-01-11
WO2018104718A1 (en) 2018-06-14
CA3044797A1 (en) 2018-06-14
CO2019006979A2 (es) 2019-09-09
GB201620611D0 (en) 2017-01-18
HUE052766T2 (hu) 2021-05-28
JP2020504713A (ja) 2020-02-13
CN110312520A (zh) 2019-10-08
US20220033457A1 (en) 2022-02-03
ZA201903003B (en) 2019-12-18
LT3548061T (lt) 2020-12-28
CL2019001512A1 (es) 2019-11-22

Similar Documents

Publication Publication Date Title
BR112019011462A2 (pt) peptídeo coagonista de gip/glp-1, e, peptídeo para uso no tratamento e/ou profilaxia da doença de alzheimer clínica.
CL2018001089A1 (es) Sales de valbenazina y polimorfos de las mismas.
BR112019008458A2 (pt) 1,2,4-triazolonas 2,4,5-trisubstituídas.
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MX2019007587A (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
BR112018017172A2 (pt) anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau
CO2019002889A2 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas
BR112016016658A2 (pt) proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
DOP2017000191A (es) Nuevas proteínas específicas para pioverdina y pioquelina
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
CL2015002387A1 (es) Nuevos derivados de pirazol.
BR112017007063A2 (pt) ?composições e métodos para o tratamento de insônia?
CO2017000346A2 (es) Anticuerpos de unión a protofibrillas aβ
CL2019001891A1 (es) Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas.
BR112019006887A2 (pt) ativadores do fluxo autofágico e fosfolipase d e depuração de agregado proteico, incluindo tau e tratamento de proteinopatias
BR112018067946A2 (pt) formulações tópicas contendo ciclosporina e usos das mesmas
EA201990400A1 (ru) Соединения и композиции и их применение
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2017012397A (es) Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache).
BR112019000946A2 (pt) compostos para imagiologia dos agregados da proteína tau
BR112016022575A2 (pt) Composições e métodos para o tratamento de doenças neurodegenerativas
MX345534B (es) Compuestos y combinaciones farmaceuticas para el tratamiento de enfermedades cerebrales isquemicas y neurodegenerativas.
MX2020009566A (es) Compuestos como moduladores de la se?alizacion de tlr2.
CO2021013171A2 (es) Compuestos y composiciones como moduladores de la señalización de tlr

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]